Post-marketing Clinical Safety Study of Naoxintong capsule by Centralized Hospital Monitoring

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17013912

Enrollment

Unknown

Registered

2017-12-14

Start date

2018-01-01

Completion date

Unknown

Last updated

2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADR/ADE

Interventions

Treatment group:Take Naoxintong capsule

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All inpatient and outpatient patients who were administrated of Naoxintong Capsule.

Exclusion criteria

Exclusion criteria: Patients who were not agree with the acquisition of the study required information.

Design outcomes

Primary

Measure	Time frame
ADR/ADE;	—

Countries

China

Contacts

Public ContactXuelin Li

The First Affiliated Hospital of Henan University of TCM

lixuelin450000@163.com+86 13703711133

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026